Education
About Us
Working with TipRanks
Follow Us
Idorsia Ltd (CH:IDIA)
:IDIA
IDIA Stock Chart & Stats
CHF3.62
-CHF0.05(-3.98%)
At close: 4:00 PM EST
CHF3.62
-CHF0.05(-3.98%)
Day’s Range― - ―
52-Week RangeCHF0.69 - CHF4.85
Previous CloseN/A
Volume178.76K
Average Volume (3M)2.48M
Market Cap
CHF929.20M
Enterprise ValueCHF1.94B
Total Cash (Recent Filing)CHF71.20M
Total Debt (Recent Filing)CHF1.26B
Price to Earnings (P/E)―
Beta2.27
Next Earnings
Feb 26, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding251,506,700
10 Day Avg. Volume2,649,008
30 Day Avg. Volume2,478,790
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-0.12
Price to Sales (P/S)1.33
P/FCF Ratio-0.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF5.25Price Target Upside45.03% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Differentiation And Prescribing EnvironmentDaridorexant's pharmacokinetic profile enables strong sleep improvement without next-day drowsiness, and potential descheduling of the orexin antagonist class could ease prescribing and accelerate commercial uptake.
Latin America Licensing And RevenueExclusive license and supply agreement with Brazil's largest private pharmaceutical company will expand daridorexant's commercial reach across Latin America and generate milestone payments, royalties, and supply revenue that strengthen near-term cash position.
Regulatory Endorsement And Partnership AppealHealth Canada marketing authorization for aprocitentan validates the product's clinical profile and increases its attractiveness to potential North American commercial partners, supporting regional partnership discussions to broaden patient access.
Bears Say
Late-stage Clinical Trial RiskFailure of late-stage trials for key drug candidates could materially reduce pipeline value and prompt negative investor reassessment.
Regulatory Approval UncertaintyInability to obtain approvals for important assets would limit market access and revenue potential despite encouraging clinical data.
Strategic Partner And Financing RiskLack of support from strategic partners could impede commercialization plans and force additional financing measures that dilute shareholder value.
IDIA FAQ
What was Idorsia Ltd’s price range in the past 12 months?
Idorsia Ltd lowest stock price was CHF0.69 and its highest was CHF4.85 in the past 12 months.
What is Idorsia Ltd’s market cap?
Idorsia Ltd’s market cap is CHF929.20M.
When is Idorsia Ltd’s upcoming earnings report date?
Idorsia Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 21 days.
How were Idorsia Ltd’s earnings last quarter?
Idorsia Ltd released its earnings results on Oct 30, 2025. The company reported -CHF0.275 earnings per share for the quarter, missing the consensus estimate of -CHF0.22 by -CHF0.055.
Is Idorsia Ltd overvalued?
According to Wall Street analysts Idorsia Ltd’s price is currently Undervalued.
Does Idorsia Ltd pay dividends?
Idorsia Ltd pays a Notavailable dividend of CHF11.841 which represents an annual dividend yield of N/A. See more information on Idorsia Ltd dividends here
What is Idorsia Ltd’s EPS estimate?
Idorsia Ltd’s EPS estimate is -0.2.
How many shares outstanding does Idorsia Ltd have?
Idorsia Ltd has 251,506,700 shares outstanding.
What happened to Idorsia Ltd’s price movement after its last earnings report?
Idorsia Ltd reported an EPS of -CHF0.275 in its last earnings report, missing expectations of -CHF0.22. Following the earnings report the stock price went down -1.63%.
Which hedge fund is a major shareholder of Idorsia Ltd?
Currently, no hedge funds are holding shares in CH:IDIA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Idorsia Ltd
Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
IDIA Stock 12 Month Forecast
Average Price Target
CHF5.25
▲(45.03% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
Options Prices
Currently, No data available
---